Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
Previous revision
cl:3-mild-neurocog-disorder [on April 25, 2020]
cl:3-mild-neurocog-disorder [on January 2, 2024] (current)
psychdb [Subtypes]
Line 2: Line 2:
 {{INLINETOC}} {{INLINETOC}}
 ===== Primer ===== ===== Primer =====
-**Mild Neurocognitive Disorder** (also known as **Mild Cognitive Impairment**,​ or MCI) is a condition in which individuals demonstrate cognitive impairment with minimal impairment of instrumental activities of daily living (IADLs). Although it can be the first cognitive sign of [[geri:​dementia:​alzheimers|]],​ it can also be secondary to other disease processes (e.g. - neurologic, other neurodegenerative disorders, systemic, infectious, or psychiatric disorders). When there is //significant// impairment to daily function, a [[cl:​2-major-neurocog-disorder|major neurocognitive disorder]] needs to be considered instead.+**Mild Neurocognitive Disorder** (also known as **Mild Cognitive Impairment**,​ or MCI) is a condition in which individuals demonstrate cognitive impairment with minimal impairment of instrumental activities of daily living (IADLs). Although it can be the first cognitive sign of [[geri:​dementia:​alzheimers|]],​ it can also be secondary to other disease processes (e.g. - neurologic, other neurodegenerative disorders, systemic, infectious, or psychiatric disorders). When there is //interference// with independence in everyday activities, a [[cl:​2-major-neurocog-disorder|major neurocognitive disorder]] needs to be considered instead.
  
-===== Diagnostic Criteria =====+<​HTML>​ 
 +<script async src="​https://​pagead2.googlesyndication.com/​pagead/​js/​adsbygoogle.js"></​script>​ 
 +<!-- Leaderboard --> 
 +<ins class="​adsbygoogle"​ 
 +     style="​display:​block"​ 
 +     ​data-ad-client="​ca-pub-8020066590182443"​ 
 +     ​data-ad-slot="​1227446251"​ 
 +     ​data-ad-format="​auto"​ 
 +     ​data-full-width-responsive="​true"></​ins>​ 
 +<​script>​ 
 +     ​(adsbygoogle = window.adsbygoogle || []).push({});​ 
 +</​script>​ 
 +</​HTML>​ 
 + 
 +== Epidemiology == 
 +  * Prevalence is between 10-20% in adults over 65 years. 
 + 
 +== Prognosis == 
 +  * Anywhere between 3 to 13% of patients with mild neurocognitive disorder will progress to a major neurocognitive disorder (dementia) each year.[([[https://​www.ncbi.nlm.nih.gov/​pmc/​articles/​PMC2863139/​|Farias,​ S. T., Mungas, D., Reed, B. R., Harvey, D., & DeCarli, C. (2009). Progression of mild cognitive impairment to dementia in clinic-vs community-based cohorts. Archives of neurology, 66(9), 1151-1157.]])] 
 +  * Not all individuals with MCI will go on to develop a dementia! 
 +    * This is a highly heterogeneous group with variable rates of conversion to dementia. 
 +    * For example, having multiple domain MCI appears to increase the risk of future dementia. 
 + 
 +== Comorbidity == 
 +  * Neuropsychiatric symptoms will be present in 35-75% of cases. 
 + 
 +== Risk Factors == 
 +  * Higher age, the presence of at least one ApoE4 allele, and medicated hypertension are independent risk factors for MCI.[([[https://​pubmed.ncbi.nlm.nih.gov/​14739544/​|Tervo,​ S., Kivipelto, M., Hänninen, T., Vanhanen, M., Hallikainen,​ M., Mannermaa, A., & Soininen, H. (2004). Incidence and risk factors for mild cognitive impairment: a population-based three-year follow-up study of cognitively healthy elderly subjects. Dementia and geriatric cognitive disorders, 17(3), 196-203.]])] 
 +  * Higher education is a protective factor for MCI. 
 + 
 +===== DSM-5 Diagnostic Criteria =====
 <WRAP group> <WRAP group>
 <WRAP half column> <WRAP half column>
Line 11: Line 41:
   - Concern of the individual, a knowledgeable informant, or the clinician that there has been a significant decline in cognitive function; and   - Concern of the individual, a knowledgeable informant, or the clinician that there has been a significant decline in cognitive function; and
   - A substantial impairment in cognitive performance,​ preferably documented by standardized neuropsychological testing or, in its absence, another quantified clinical assessment.   - A substantial impairment in cognitive performance,​ preferably documented by standardized neuropsychological testing or, in its absence, another quantified clinical assessment.
 +</​WRAP>​
 +<WRAP half column>
  
 == Criterion B == == Criterion B ==
-The cognitive deficits **//do not interfere with capacity for independence in everyday activities//​** (i.e.complex instrumental activities of daily living such as paying bills or managing medications are preserved, but greater effort, compensatory strategies, or accommodation may be required).+The cognitive deficits **//do not interfere with capacity for independence in everyday activities//​** (i.e. complex instrumental activities of daily living such as paying bills or managing medications are preserved, but greater effort, compensatory strategies, or accommodation may be required).
  
 == Criterion C == == Criterion C ==
-The cognitive deficits do not occur exclusively in the context of a delirium.+The cognitive deficits do not occur exclusively in the context of a [[cl:1-delirium|delirium]].
  
 == Criterion D == == Criterion D ==
 The cognitive deficits are not better explained by another mental disorder (e.g., [[mood:​1-depression:​home|major depressive disorder]], [[psychosis:​schizophrenia-scz|schizophrenia]]). The cognitive deficits are not better explained by another mental disorder (e.g., [[mood:​1-depression:​home|major depressive disorder]], [[psychosis:​schizophrenia-scz|schizophrenia]]).
 </​WRAP>​ </​WRAP>​
-<​WRAP ​half column>+</WRAP>
  
-== Specifiers == +==== Specifiers ​==== 
-<accordion collapsed="​false"​>+<WRAP group> 
 +<WRAP half column>
 <panel icon="​fa fa-search-plus"​ size="​xs"​ title="​Etiology Specifier">​ <panel icon="​fa fa-search-plus"​ size="​xs"​ title="​Etiology Specifier">​
   * Major or Mild Neurocognitive Disorder Due to [[geri:​dementia:​alzheimers|Alzheimer’s Disease]]   * Major or Mild Neurocognitive Disorder Due to [[geri:​dementia:​alzheimers|Alzheimer’s Disease]]
Line 40: Line 73:
   * Unspecified Neurocognitive Disorder   * Unspecified Neurocognitive Disorder
 </​panel>​ </​panel>​
 +</​WRAP>​
 +<WRAP half column>
 <panel icon="​fa fa-signal"​ size="​xs"​ title="​Behaviour Specifier">​ <panel icon="​fa fa-signal"​ size="​xs"​ title="​Behaviour Specifier">​
 **Specify:​** **Specify:​**
   * **Without behavioural disturbance**:​ If the cognitive disturbance is not accompanied by any clinically significant behavioral disturbance.   * **Without behavioural disturbance**:​ If the cognitive disturbance is not accompanied by any clinically significant behavioral disturbance.
-  * **With behavioural disturbance** (//specify disturbance//​):​ If the cognitive disturbance is accompanied by a clinically significant behavioural disturbance (e.g.psychotic symptoms, mood disturbance,​ agitation, apathy, or other behavioural symptoms).+  * **With behavioural disturbance** (//specify disturbance//​):​ If the cognitive disturbance is accompanied by a clinically significant behavioural disturbance (e.g. psychotic symptoms, mood disturbance,​ agitation, apathy, or other behavioural symptoms).
 </​panel>​ </​panel>​
-</accordion>+</WRAP> 
 +</WRAP>
  
-</WRAP><​/WRAP>+===== Subtypes ===== 
 +The DSM-5 diagnostic criteria notably do not provide additional sub-typing of MCI beyond the specifier criteria or how [[cognitive-testing:​memory|cognitive domains]] are specifically involved. Outside of the DSM-5, a total of ''​4''​ MCI subtypes have been proposed, depending on whether the presentation is amnestic/non-amnestic,​ and single/multiple domain:​[([[https://​www.ncbi.nlm.nih.gov/​pmc/​articles/​PMC2929315/​|Rapp,​ S. R., Legault, C., Henderson, V. W., Brunner, R. L., Masaki, K., Jones, B., ... & Thal, L. (2010). Subtypes of mild cognitive impairment in older postmenopausal women: the Women’s Health Initiative Memory Study. Alzheimer disease and associated disorders, 24(3), 248.]])] 
 +  - **Amnestic MCI, Single Domain (a-MCI-sd)**\ 
 +    * **a-MCI-sd** involves primarily memory impairment with no or minimal involvement of the other cognitive domains. 
 +  - **Amnestic MCI, Multiple Domain (a-MCI-md)** 
 +    * **a-MCI-md** involves memory impairment as the primary domain affected, but other cognitive domains (e.g. - executive function, attention, language, decision-making,​ judgment, visuospatial) are also impaired. 
 +  - **Non-Amnestic MCI, Single Domain (na-MCI-sd)** 
 +    * **na-MCI-sd** involves impairment of a single, non-memory cognitive domain, such executive function, attention, language, or visuospatial skills. 
 +  - **Non-Amnestic MCI, Multiple Domain (na-MCI-md)** 
 +    * **na-MCI-md** involves impairment of two or more cognitive domains, neither of which involves memory impairment.
  
 +===== Differential Diagnosis =====
 +<alert icon="​fa fa-arrow-circle-right fa-lg fa-fw" type="​success">​
 +See main article: **[[geri:​dementia:​home|]]**
 +</​alert>​
 +
 +  * Some cases of MCI are actually reversible causes of cognitive impairment. This is a broad differential diagnosis that includes medication side effects, [[sleep:​breathing:​1-osa|obstructive sleep apnea]], [[mood:​1-depression:​geriatric|depression]] (pseudodementia),​ and other medical conditions. Medications such as [[meds:​benzos:​home|benzodiazepines]] may also contribute to cognitive impairment and so [[meds:​benzos:​deprescribe-tapering|deprescribing]] may also be an important factor to consider.
 ===== Management ===== ===== Management =====
-See [[https://​www.ncbi.nlm.nih.gov/​pubmed/​29282327|Petersen,​ Ronald C., et al. Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development,​ Dissemination,​ and Implementation Subcommittee of the American Academy of Neurology. Neurology 90.3 (2018): 126-135.]]+<alert type="​info"​ icon="​fa fa-book fa-lg fa-fw">​ 
 +See also: **[[https://​www.ncbi.nlm.nih.gov/​pubmed/​29282327|Petersen,​ Ronald C., et al. Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development,​ Dissemination,​ and Implementation Subcommittee of the American Academy of Neurology. Neurology 90.3 (2018): 126-135.]]** 
 +</​alert>​ 
 + 
 + 
 + 
 +==== Monitoring and Counselling ==== 
 +  * Clinicians should counsel patients with MCI and their families to discuss long-term planning topics such as advance directives, driving safety, finances, and estate planning.[([[https://​www.ncbi.nlm.nih.gov/​pmc/​articles/​PMC5772157/​|Petersen,​ R. C., Lopez, O., Armstrong, M. J., Getchius, T. S., Ganguli, M., Gloss, D., ... & Rae-Grant, A. (2018). Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development,​ Dissemination,​ and Implementation Subcommittee of the American Academy of Neurology. Neurology, 90(3), 126-135.]])] 
 +  * For patients diagnosed with MCI, clinicians should perform serial cognitive assessments over time (e.g., a [[cognitive-testing:​moca|MoCA]] every 6 to 12 months) to monitor for changes in cognitive status.[([[https://​www.ncbi.nlm.nih.gov/​pmc/​articles/​PMC5772157/​|Petersen,​ R. C., Lopez, O., Armstrong, M. J., Getchius, T. S., Ganguli, M., Gloss, D., ... & Rae-Grant, A. (2018). Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development,​ Dissemination,​ and Implementation Subcommittee of the American Academy of Neurology. Neurology, 90(3), 126-135.]])] 
 +  * [[geri:​dementia:​1-bpsd|Neuropsychiatric symptoms]] should also be serially assessed for, as these may be more functionally impairing than the cognitive symptoms. 
 + 
 +==== Exercise ==== 
 +  * [[teaching:​exercise-prescription|Exercise]] at least twice weekly of moderate intensity may provide benefits in cognition for individuals with MCI.[([[https://​www.ncbi.nlm.nih.gov/​pmc/​articles/​PMC5772157/​|Petersen,​ R. C., Lopez, O., Armstrong, M. J., Getchius, T. S., Ganguli, M., Gloss, D., ... & Rae-Grant, A. (2018). Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development,​ Dissemination,​ and Implementation Subcommittee of the American Academy of Neurology. Neurology, 90(3), 126-135.]])]
  
-===== Treatment ===== +==== Pharmacologic ​==== 
-== Vitamin D == +  * There are no high-quality, ​long-term ​studies suggesting that either pharmacologic or dietary agents can improve cognition or delay progression in patients with MCI.[([[https://​www.ncbi.nlm.nih.gov/​pmc/​articles/​PMC5772157/|Petersen, R. C., Lopez, O., Armstrong, M. J., Getchius, T. S., Ganguli, M., Gloss, D., ... & Rae-GrantA. (2018). ​Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development,​ Dissemination,​ and Implementation Subcommittee of the American Academy of Neurology. Neurology, 90(3), 126-135.]])] 
-Improvements in cognition and lipid levels ​are seen in individuals with long-term ​supplementation of Vitamin D.[([[https://​www.ncbi.nlm.nih.gov/​pubmed/30279214|FujishiroH. (2018). ​Vitamin D3 as a potentially modifiable factor in mild cognitive ​impairment. J Neurol Neurosurg Psychiatryjnnp-2018.]])]+  * [[meds:​dementia:​home|Acetylcholinesterase inhibitors]] ​as a class have shown **no benefit** on cognitive ​outcomes or reduction in progression from MCI to dementia (although some studies could not entirely exclude a positive effect). In addition to lacking efficacy, the side effects of cholinesterase inhibitors can be significant.[([[https://​www.ncbi.nlm.nih.gov/​pmc/​articles/​PMC5772157/​|Petersen,​ R. C., Lopez, O., Armstrong, M. J.Getchius, T. S., Ganguli, M., Gloss, D., ... & Rae-Grant, A. (2018). Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development,​ Dissemination,​ and Implementation Subcommittee of the American Academy of Neurology. Neurology, 90(3), 126-135.]])] If an individual is prescribed an acetylcholinesterase inhibitor, they should be counselled that this is off-label.